Evidence map›Paper›PMID 28886748›Full record

ArticleBreast cancer research : BCR2017

ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.

Michelle M Williams, David B Vaught, Meghan Morrison Joly, Donna J Hicks, Violeta Sanchez, Philip Owens, Bushra Rahman, David L Elion, Justin M Balko, Rebecca S Cook

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Whole-Genome Resequencing Analysis of theInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Busting the Breast Cancer with AstraZeneca's Gefitinib.Advances in pharmacological and pharmaceutical sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Michelle M WilliamsDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
David B VaughtDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
Meghan Morrison JolyDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
Donna J HicksDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
Violeta SanchezDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Philip OwensDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
Bushra RahmanDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
David L ElionDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA.
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Rebecca S CookDepartment of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Rm 749 Preston Research Building, Nashville, TN, 37232, USA. Rebecca.cook@vanderbilt.edu.
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Vanderbilt/Meharry Initiative for Minority Student DvptR25GM062459 · NIGMS · VANDERBILT UNIVERSITY · PI VELEZ EDWARDS, DIGNA R · 2002 to 2020
$10.4M
Mcl-1 drives resistance of luminal breast cancers to targeted therapiesF31CA195989 · NCI · VANDERBILT UNIVERSITY · PI WILLIAMS, MICHELLE M · 2015 to 2016
$57k
Advancing Opportunities for Ped. Research and the Role of CC-CHOC within NCATSU13TR000044 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KASKEL, FREDERICK JEFFREY · 2013 to 2013
$30k
Linking Clinical Translational Science Award Sites to Improve Pediatric ResearchR13TR000044 · NCATS · VANDERBILT UNIVERSITY · PI BARKIN, SHARI · 2012 to 2012
$23k
NCATS NIH HHS R13 TR000044NCATS NIH HHS U13 TR000044NCATS NIH HHS UL1 TR000445NCI NIH HHS F31 CA195989NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NIGMS NIH HHS R25 GM062459
6 · The paper itself

Abstract

backgroundDuring pregnancy, as the mammary gland prepares for synthesis and delivery of milk to newborns, a luminal mammary epithelial cell (MEC) subpopulation proliferates rapidly in response to systemic hormonal cues that activate STAT5A. While the receptor tyrosine kinase ErbB4 is required for STAT5A activation in MECs during pregnancy, it is unclear how ErbB3, a heterodimeric partner of ErbB4 and activator of phosphatidyl inositol-3 kinase (PI3K) signaling, contributes to lactogenic expansion of the mammary gland.

methodsWe assessed mRNA expression levels by expression microarray of mouse mammary glands harvested throughout pregnancy and lactation. To study the role of ErbB3 in mammary gland lactogenesis, we used transgenic mice expressing WAP-driven Cre recombinase to generate a mouse model in which conditional ErbB3 ablation occurred specifically in alveolar mammary epithelial cells (aMECs).

resultsProfiling of RNA from mouse MECs isolated throughout pregnancy revealed robust Erbb3 induction during mid-to-late pregnancy, a time point when aMECs proliferate rapidly and undergo differentiation to support milk production. Litters nursed by ErbB3

conclusionsThese studies demonstrate that ErbB3, like ErbB4, enhances lactogenic expansion and differentiation of the mammary gland during pregnancy, through activation of Akt and STAT5A, two targets crucial for lactation.

Indexed as

AllelesAnimalsBreastCell DifferentiationCell ProliferationCell SurvivalEpithelial CellsFemaleGene Knockout TechniquesImmunohistochemistryLactationMiceMice, TransgenicPhosphatidylinositol 3-KinasesPregnancyProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, ErbB-3Receptor, ErbB-4RNA, MessengerSTAT5 Transcription FactorAktAlveolar mammary epithelial cellErbB3ErbB4Jak2LactationMammary gland developmentPI3 kinaseProlactinSTAT5A

Identifiers

PMID28886748
PMCPMC5591538
OpenAlexW2752389752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.